Lei Qian, Xiao Ding, Fang-Qi Li, Hui-Min Tian, Xiao Chen, Fu-Jun Han, Hong-Yi Wang, Wen-Qian Li, Chao Niu, Jian-Ting Xu, Zhao-Zhi Li, Hua He, Jiu-Wei Cui
Platinum-based chemotherapy is the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients without a driver gene mutation, but its efficacy is still modest. Through a potential synergistic effect, autologous cellular immunotherapy (CIT) composed of cytokine-induced killer (CIK, natural killer (NK), and T cells) might enhance it. NK cells exhibited in vitro cytotoxicity toward lung cancer cells (A549 cells) following platinum therapy. Using flow cytometry, the expression of MICA, MICB, DR4, DR5, CD112, and CD155 on lung cancer cells was assessed...
March 30, 2023: Neoplasma